Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Completed
National Cancer Institute (NCI)
Phase 2
2004-04-01
This phase II trial is studying how well medroxyprogesterone works in treating patients with
endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not
including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating
endometrioid cancer.
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Completed
Gynecologic Oncology Group
Phase 2
2004-04-01
This phase II trial is studying how well medroxyprogesterone works in treating patients with
endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not
including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating
endometrioid cancer.
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
Completed
Translational Breast Cancer Research Consortium
Phase 2
2007-07-01
The purpose of this study is to evaluate the impact of MPA alone and in combination with low
dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
Completed
Indiana University
Phase 2
2007-07-01
The purpose of this study is to evaluate the impact of MPA alone and in combination with low
dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
